SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity; a randomised, double-blind, parallel group, placebo-controlled trial comparing semaglutide 2.4 mg with semaglutide placebo both administered s.c. once-weekly in subjects with established CV disease and overweight or obesity
A randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (etc-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant
A Phase 2, double-blind, placebo-controlled, randomized study to compare the efficacy and safety of sotatercept (ACE-011) versus placebo when added to standard of care for the treatment of pulmonary arterial hypertension (PAH)
"A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy"
A multi-center, randomized, double-blind, phase IV clinical trial on the diuretic effects of Acetazolamide (Diamox ®) in patients with Decompensated heart failure and Volume OveRload
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF)
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF)
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF)
Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation – in atrial fibrillation (ENVISAGE-TAVI-AF)
Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement.
A randomised controlled trial of Rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS- Cardiovascular OutcoMes for People using Anticoagulation StrategieS) - Long-Term Open-Label Extension (LTOLE).
Evaluation of the safety and efficacy of an edoxaban based compared to a vitamin K antagonist based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent placement